marketing wars over the new sleeping pills
You'll see marketing wars over the new sleeping pills... Lunesta, Rozerem, Ambien CR, and then indiplon next year.
Lunesta (eszopiclone) is making a big splash now to get a head start. It's the first one approved for long-term use...but it has a bitter aftertaste in up to 30% of patients.
Rozerem (ro-ZER-um) will be out this month. It's the first in a new class...melatonin receptor agonists.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote